[CAS NO. 68401-82-1] Ceftizoxime sodium
PRODUCTS SPECIFICATIONS [68401-82-1]
DESCRIPTION [68401-82-1]
Overview
| MDL | MFCD01682036 |
|---|---|
| Molecular Weight | 405.38 |
| Molecular Formula | C13H12N5NaO5S2 |
| SMILES | O=C(C(N12)=CCS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O[Na] |
Summary
Ceftizoxime sodium (SKF-88373) is third generation cephalosporin effective against Gram-negative and Gram-positive bacteria. It binds penicillin-binding proteins (PBPs) and inhibits the bacterial cell wall synthesis.
IC50 & Target
Antibacterial
In Vitro
Ceftizoxime is a third-generation cephalosporin available for parenteral administration. Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01347593 | University of Khartoum|Ministry of Health, Sudan |
Caesarean
|
May 2011 | Phase 4 |
| NCT04771884 | Shandong University|Children´s Hospital of Chongqing Medical University |
Bacterial Meningitis|Augmented Renal Clearance
|
October 1, 2020 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
H 2 O : 100 mg/mL ( 246.68 mM ; Need ultrasonic)
DMSO : 15 mg/mL ( 37.00 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4668 mL | 12.3341 mL | 24.6682 mL |
| 5 mM | 0.4934 mL | 2.4668 mL | 4.9336 mL |
| 10 mM | 0.2467 mL | 1.2334 mL | 2.4668 mL |
Synonyms